<DOC>
	<DOCNO>NCT02633163</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety mesenchymal stem cell ( MSCs ) obtain umbilical cord treatment adult systemic lupus erythematosus ( SLE ) . The goal study determine patient receive MSC infusion plus standard care respond well patient receive placebo infusion plus standard care .</brief_summary>
	<brief_title>MsciSLE : MSCs SLE Trial</brief_title>
	<detailed_description>A phase 2 multicenter ( several medical research center participate ) , placebo control , randomize ( assigned chance ) , double blind ( neither participant investigator know active drug placebo assign ) trial evaluate safety efficacy mesenchymal stem cell ( MSCs ) treatment systemic lupus erythematosus ( SLE ) adult . The MSCs obtain healthy donor umbilical cord two dos MSCs test . The cell produce Medical University South Carolina ( MUSC ) ship participate center patient SLE . Participants receive either active drug placebo single IV infusion . All participant receive standard care safety monitor throughout study .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Plasma-lyte 148</mesh_term>
	<criteria>Patients 18 65 year old , male female , race Historical presence least 4 11 ACR Classification Criteria 34 Evidence positive ANA ( ≥1:80 titer ) positive dsDNA antibody test within 6 month screen Clinically active SLE determine SLEDAI score ≥6 presence one BILAG A two BILAG Bs screening , despite standard care therapy If BILAG A two BILAG Bs Renal organ system , must complete least 6 month therapy either mycophenolate mofetil cyclophosphamide current episode nephritis Able willing give write informed consent Active CNS lupus affect mental status Active lupus nephritis require dialysis Laboratory exclusion : eGFR &lt; 30 , WBC &lt; 2.0/mm3 , hemoglobin &lt; 8 g/dL , platelet count &lt; 30,000/mm3 , liver enzymes AST ALT &gt; 4 time upper limit normal ; Positive test HIV , hepatitis B hepatitis C History malignant neoplasm within last 3 year , except adequately treat cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . Pregnant breast feeding ; male female willing use adequate contraception History renal transplantation Herpes zoster within past 90 day infection require hospitalization intravenous antibiotic within past 60 day Clinically significant EKG chest xray change Any medical condition , relate unrelated SLE , opinion investigator would render patient inappropriate unstable complete study protocol Use prednisone &gt; 0.5 mg/kg/day ( equivalent corticosteroid ) within 1 month Baseline visit Change addition immunosuppressant regimen within 3 month Baseline visit ( except corticosteroid ) ; Use experimental therapeutic agent within 3 month Baseline visit Having receive belimumab within 2 month Baseline , receive rituximab B cell deplete biologic therapy within 6 month Baseline . Comorbidities require corticosteroid therapy Current substance abuse recent ( within 60 day ) history substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Lupus</keyword>
</DOC>